Hoi Marion,
Oh, I see …. afwachten dus nog…. spannend ….
Wel mooi (ivm met de operatie ook) dat je gezondheid in het algemeen toch goed is gebleven – mede door de goede nutrienten status! – en hopelijk is er ook nog wat te verbeteren weer ivm de evt ontkalking van de botten door de vitamine K tekorten (heb je al uitslag van de scan?).
Je hebt nu nog wat tijd dus om je ook “orthomoleculair” op de blijkbaar toch onvermijdelijke transplantatie voor te bereiden (vooraf, ….en er na) …. neem je al Q10 eigenlijk??
Voor jou gevonden:
Department of Cardiothoracic Surgery, Heart-Lung Transplant Unit, Rabin Medical Center, Beilinson Campus, Potah Tikva, Israel. mariusby@yahoo.com
Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study.
BACKGROUND: The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure.
HYPOTHESIS: The purpose of the present double-blind, placebo-controlled, randomized study was to assess the effect of CoQ10 on patients with end-stage heart failure and to determine if CoQ10 can improve the pharmacological bridge to heart transplantation.
METHODS: A prospective double-blind design was used. Thirty-two patients with end-stage heart failure awaiting heart transplantation were randomly allocated to receive either 60 mg U/day of Ultrasome–CoQ10 (special preparation to increase intestinal absorption) or placebo for 3 months. All patients continued their regular medication regimen. Assessments included anamnesis with an extended questionnaire based partially on the Minnesota Living with Heart Failure Questionnaire, 6-min walk test, blood tests for atrial natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography.
RESULTS: Twenty-seven patients completed the study. The study group showed significant improvement in the 6-min walk test and a decrease in dyspnea, New York Heart Association (NYHA) classification, nocturia, and fatigue. No significant changes were noted after 3 months of treatment in echocardiography parameters (dimensions and contractility of cardiac chambers) or ANF and TNF blood levels.
CONCLUSIONS: The administration of CoQ10 to heart transplant candidates led to a significant improvement in functional status, clinical symptoms, and quality of life. However, there were no objective changes in echo measurements or ANF and TNF blood levels.
Coenzyme Q10 may serve as an optional addition to the pharmacologic armamentarium of patients with end-stage heart failure. The apparent discrepancy between significant clinical improvement and unchanged cardiac status requires further investigation.
http://www.ncbi.nlm.nih.gov/pubmed/15188947
Let wel: in deze studie is maar 60 mg Q10 gebruikt. Dat is best vrij weinig.
Er zijn ook studies van Q10 bij hartfalen gedaan met een dosis van 390 mg.
Ik nam zelf eerst 100 mg en nu 200 mg, en merk het verschil (mijn EF was ca 27).
Nou Marion, nogmaals veel sterkte en succes, en als ik je ergens mee kan helpen (bv met info zoeken 🙂 ) dan hoor ik het wel.
Veel Liefs :kiss:
Lisa.
.
